Acer Therapeutics

Acer Therapeutics, Inc. is a pharmaceutical company. engages in acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS).  The company was founded in 2013 and is headquartered in Newton, Massachusetts.

TAIPEI , Aug. 8, 2024 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its financial results for the second quarter of 2024. Consolidated revenues reached NT$67.14 billion, up 15.2% year-on-year (YoY); operating income was NT$1.47 billion, up 87.9% quarter-on-quarter (QoQ) and 40.3% YoY, with 2.2% margin; net income[1] was NT$1.40 billion with earnings-per-share NT$0.47.

Acer Announces Q2 2024 Operating Income at NT$1.47 Billion, Up 87.9% Quarter-on-quarter and 40.3% Year-on-year

NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co. LLC (Glass Lewis) recommended that Acer shareholders vote "FOR" the proposed merger with Zevra Therapeutics, Inc. and the related proposals in the Company's proxy statement and prospectus for the special meeting of its shareholders to be held on November 8, 2023 at 11:00 a.m.

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals

Margins for gross profit, operating income, and net income all grow both year-on-year and quarter-on-quarter TAIPEI , Nov. 2, 2023 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its financial results for the third quarter of 2023: consolidated revenues were NT$67.44 billion with 15.8% growth quarter-on-quarter (QoQ) and 3.9% growth year-on-year (YoY); gross profits reached NT$7.29 billion with 10.8% margin, higher than both the previous quarter and the same period last year; operating income was NT$1.55 billion, up 47.8% QoQ and 86.6% YoY, with 2.3% margin; net income[1] was NT$2.01 billion, up 44.2% QoQ and 7.0% YoY; and earnings per share was NT$0.67. In the third quarter, businesses other than computers and displays contributed 24.2% of total revenues, and 30.0% of operating income.

Acer Announces Q3 2023 Net Income at NT$2.01 Billion, up 44.2% Quarter-on-quarter

Acer CEO Jason Chen said that PC demand hit a bottom in May, but demand has come back since then.

PC demand is back, says Acer CEO who sees robust growth in the 'foreseeable future'

Zevra Therapeutics Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA). Under the terms of the proposed transaction, shareholders of Acer will receive 0.121 shares of Zevra for each share of Acer that they own. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights.

ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER

Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.

Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up

MILWAUKEE , Aug. 31, 2023 /PRNewswire/ -- Ademi LLP is investigating Acer (Nasdaq: ACER) for possible breaches of fiduciary duty and other violations of law in its transaction with Zevra. Click here to learn how to join the action https://www.ademilaw.com/case/acer-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Acer Therapeutics Inc. has obtained a Fair Price in its transaction with Zevra

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Acer Therapeutics Inc. (NASDAQ: ACER) to Zevra Therapeutics, Inc. for 0.121 of a share of Zevra's common stock for each share of Acer's common stock is fair to Acer shareholders. Additionally, Acer stockholders would receive non-transferable Contingent Value Rights entitling them to receive up to $34 million in cash upon the achievement of certain commercial milestones for OLPRUVA, and.

ACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to Shareholders

Acer Therapeutics (NASDAQ: ACER ) stock is taking off on Thursday after the pharmaceutical company announced an acquisition deal with Zevra Therapeutics (NASDAQ: ZVRA ). According to a press release from the company, Zevra Therapeutics will be acquiring it with $15 million worth of ZVRA stock.

Why Is Acer Therapeutics (ACER) Stock Up 85% Today?

NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has entered into definitive agreements to reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union, Liechtenstein, San Marino, Vatican City, Norway, Iceland, Principality of Monaco, Andorra, Gibraltar, Switzerland, United Kingdom, Albania, Bosnia, Kosovo, Montenegro, Serbia and North Macedonia (Geographical Europe). OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).

Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe

OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients OLPRUVA™ (sodium phenylbutyrate) kits now available in all dosage strengths and ready to ship to patients

Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Promissory note extends cash runway into early Q3 2023 OLPRUVA™ expected to be available by prescription in the U.S. beginning July 5 th NEWTON, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has received $1,000,000 in funding in exchange for the issuance of an unsecured, subordinated promissory note for that principal amount to Christopher Schelling, the Company's Chief Executive Officer and Founder, a member of the Company's Board of Directors, and the beneficial owner of more than 10% of the Company's outstanding common stock.

Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder

U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023

Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update

Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at SIMD Annual Meeting indicated an interest in treating at least one of their patients with OLPRUVA™ in 2023 Reimbursement: Acer engaged in discussions with payers representing a substantial majority of covered lives NEWTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced an update on progress in support of its commercial launch of OLPRUVA™ (sodium phenylbutyrate) for oral suspension, including drug availability now expected earlier than anticipated in mid-June 2023, subject to additional capital.

Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule

NEWTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for Q4 and full year ended December 31, 2022, and provided an update on the Company's recent corporate developments.

Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update

Results from survey of Urea Cycle Disorders (UCD) healthcare providers show taste and odor were the most important attributes when considering treatment options and treatment adherence Results from survey of Urea Cycle Disorders (UCD) healthcare providers show taste and odor were the most important attributes when considering treatment options and treatment adherence

Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes

NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company's common stock (or common stock equivalents) at a purchase price of $0.916 per share of common stock (or common stock equivalent) in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue warrants to purchase up to 2,920,306 shares of common stock. The warrants will have an exercise price of $0.791 per share, will be exercisable immediately following issuance and have a term of five and one-half years from the issuance date.

Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

ACER's Stock Down on Failure of Phase II Study, Cash Updates

ACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women ACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women

Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial

Results to be presented from a survey designed to quantify treatment preferences of healthcare providers for Urea Cycle Disorders (UCDs)

Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update

Advanced Emissions Solutions

Applied Blockchain Inc

Blackboxstocks

TD Holdings Inc

P. H. Glatfelter Company

Porch Group

When it comes to penny stocks, a diligent look at fundamentals and insider activity should be key to your research. After all, penny stocks with strong insider buying can potentially be strong opportunities.

7 Penny Stocks With Strong Insider Buying Signals

Topline trial results expected mid-March 2023 Topline trial results expected mid-March 2023

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Assertio Therapeutics Inc

Dyne Therapeutics

Alaunos Therapeutics

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.

5 Stocks to Buy as the Drug Industry Bets Big on Innovation

Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?

NEWTON, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023.

News for Acer Therapeutics Stock (ACER)